Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01792505 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
A Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT01792505 is a Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 71 participants.
The verdict
NCT01792505, a Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 24 months. The current standard treatment of surgical resection followed by radiation therapy and chemotherapy has not substantially prolonged survival and even the few treatment options shown to exhibit small increases in survival primarily benefit certain (i.e., young) patient subpopulations. Cancer vaccines represent one novel therapy for malignant gliomas. The goal is for the body to recognize the tumor cells are foreign and produce its own response to fight off recurring tumor cells. A promising means of causing an immune response so the body can create this immunity is through the use of dendritic cell (DC) vaccines.
Interventions
- BIOLOGICAL Dendritic Cell Vaccine in combination with Imiquimod cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2009-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01792505
The ClinicalTrials.gov registry entry for NCT01792505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dendritic Cell Vaccine in combination with Imiquimod cream is the first listed.
NCT01792505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01792505 about?
NCT01792505 is a clinical study titled "Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma". Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 24 months. The current standard treatment of surgical resection followed by radiation therapy and chemotherapy has not substantially prolonged survival and ...
What is the current status of trial NCT01792505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2009-10. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01792505?
The interventions under investigation include: Dendritic Cell Vaccine in combination with Imiquimod cream (BIOLOGICAL).
Who is sponsoring clinical trial NCT01792505?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.